FDA rejects Merck's Cordaptive

Share this article:
The FDA has issued Merck a not approvable letter regarding its developmental cholesterol-lowerer dubbed Cordaptive.

Regulators have also rejected the brand name of Cordaptive for the drug, which is also known as Mk-0524a. The drug is a combination of good-cholesterol raising vitamin niacin and laropiprant, a drug designed to lessen the facial flushing caused by niacin.

Merck said it plans to meet with the agency to provide additional data and further examine the drug's benefit-risk profile. 

Merck planned to package Cordaptive with its treatment Zocor, a $5 billion-a-year blockbuster before losing patent protection in 2006.

The failure of Cordaptive “comes as a surprise, given the publicly disclosed data,'' said Deutsche Bank analyst Barbara Ryan in a note to investors today. “Without more information, it is difficult to gauge what the FDA took issue with, or what additional data Merck could provide to gain approval.”
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.